Your browser doesn't support javascript.
loading
Clinical utility of measuring Epstein-Barr virus-specific cell-mediated immunity after HSCT in addition to virological monitoring: results from a prospective study.
Chiereghin, Angela; Piccirilli, Giulia; Belotti, Tamara; Prete, Arcangelo; Bertuzzi, Clara; Gibertoni, Dino; Gabrielli, Liliana; Turello, Gabriele; Borgatti, Eva Caterina; Barbato, Francesco; Sessa, Mariarosaria; Arpinati, Mario; Bonifazi, Francesca; Lazzarotto, Tiziana.
Afiliación
  • Chiereghin A; Department of Specialized, Experimental, and Diagnostic Medicine, Operative Unit of Clinical Microbiology, St. Orsola-Malpighi Polyclinic, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy.
  • Piccirilli G; Department of Specialized, Experimental, and Diagnostic Medicine, Operative Unit of Clinical Microbiology, St. Orsola-Malpighi Polyclinic, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy.
  • Belotti T; Unit of Pediatric Oncology and Hematology, Department of Pediatrics, St. Orsola-Malpighi Polyclinic, Via Massarenti 9, 40138, Bologna, Italy.
  • Prete A; Unit of Pediatric Oncology and Hematology, Department of Pediatrics, St. Orsola-Malpighi Polyclinic, Via Massarenti 9, 40138, Bologna, Italy.
  • Bertuzzi C; Department of Specialized, Experimental, and Diagnostic Medicine, Hematopathology Section, St. Orsola-Malpighi Polyclinic, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy.
  • Gibertoni D; Department of Biomedical and Neuromotor Sciences, Unit of Hygiene and Biostatistics, University of Bologna, Via San Giacomo 12, 40126, Bologna, Italy.
  • Gabrielli L; Operative Unit of Clinical Microbiology, St. Orsola-Malpighi Polyclinic, Via Massarenti 9, 40138, Bologna, Italy.
  • Turello G; Department of Specialized, Experimental, and Diagnostic Medicine, Operative Unit of Clinical Microbiology, St. Orsola-Malpighi Polyclinic, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy.
  • Borgatti EC; Department of Specialized, Experimental, and Diagnostic Medicine, Operative Unit of Clinical Microbiology, St. Orsola-Malpighi Polyclinic, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy.
  • Barbato F; Institute of Hematology "L. and A. Seràgnoli", St. Orsola-Malpighi Polyclinic, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy.
  • Sessa M; Institute of Hematology "L. and A. Seràgnoli", St. Orsola-Malpighi Polyclinic, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy.
  • Arpinati M; Institute of Hematology "L. and A. Seràgnoli", St. Orsola-Malpighi Polyclinic, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy.
  • Bonifazi F; Institute of Hematology "L. and A. Seràgnoli", St. Orsola-Malpighi Polyclinic, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy.
  • Lazzarotto T; Department of Specialized, Experimental, and Diagnostic Medicine, Operative Unit of Clinical Microbiology, St. Orsola-Malpighi Polyclinic, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy. tiziana.lazzarotto@unibo.it.
Med Microbiol Immunol ; 208(6): 825-834, 2019 Dec.
Article en En | MEDLINE | ID: mdl-31289930
ABSTRACT
Lack of virus-specific cell-mediated immunity (CMI) is associated with worse viral infection outcome in hematopoietic stem cell transplantation (HSCT). We aimed to evaluate the role of immunological monitoring of Epstein-Barr virus (EBV) infection in addition to virological one in 33 adult and 18 pediatric allogeneic HSCT recipients. Virological monitoring of infection was performed on whole blood samples by a quantitative real-time PCR assay. Immunological monitoring was performed by Enzyme-linked ImmunoSPOT assay, evaluating EBV-specific CMI, at fixed time-points and when EBV DNAemia was ≥ 10,000 copies/mL. Fifty-one percent of patients developed a post-transplant EBV infection and reduced-intensity conditioning regimen was the only factor associated to infection (P = 0.023). Lack of EBV-specific CMI during active EBV infection was associated with a greater severity of infection. Patients without EBV-specific CMI showed higher median peak level of EBV DNAemia than patients with EBV-specific CMI (P = 0.014), and consequently received more frequently, at EBV DNAemia peak, anti-CD20 therapy (0 versus 54.5%, P = 0.002). No patients with EBV-specific CMI versus 27.2% without EBV-specific CMI developed EBV-related complications (P = 0.063), including two lethal EBV-related post-transplant lymphoproliferative disorders. Combined immunological and virological measurements could improve EBV infection management in HSCT, anticipating the beginning of preemptive treatment from the EBV DNAemia peak to the finding of the lack of EBV-specific CMI.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Herpesvirus Humano 4 / Trasplante de Células Madre Hematopoyéticas / Infecciones por Virus de Epstein-Barr / Inmunidad Celular Tipo de estudio: Diagnostic_studies / Observational_studies / Risk_factors_studies Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Idioma: En Revista: Med Microbiol Immunol Año: 2019 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Herpesvirus Humano 4 / Trasplante de Células Madre Hematopoyéticas / Infecciones por Virus de Epstein-Barr / Inmunidad Celular Tipo de estudio: Diagnostic_studies / Observational_studies / Risk_factors_studies Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Idioma: En Revista: Med Microbiol Immunol Año: 2019 Tipo del documento: Article País de afiliación: Italia